These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 39358733)
1. Comparison of long-term quality of life and their predictors in survivors between paediatric and adult nasopharyngeal carcinoma in the intensity-modulated radiotherapy era. Jin J; Guo SS; Liu LT; Wen DX; Liu RP; Lin JY; Liu SQ; Sun XS; Liang YJ; Tang LQ; Mai HQ; Chen QY BMC Cancer; 2024 Oct; 24(1):1223. PubMed ID: 39358733 [TBL] [Abstract][Full Text] [Related]
2. Long-term late toxicities and quality of life for survivors of nasopharyngeal carcinoma treated with intensity-modulated radiotherapy versus non-intensity-modulated radiotherapy. Huang TL; Chien CY; Tsai WL; Liao KC; Chou SY; Lin HC; Dean Luo S; Lee TF; Lee CH; Fang FM Head Neck; 2016 Apr; 38 Suppl 1():E1026-32. PubMed ID: 26041548 [TBL] [Abstract][Full Text] [Related]
3. Long-Term Late Toxicity, Quality of Life, and Emotional Distress in Patients With Nasopharyngeal Carcinoma Treated With Intensity Modulated Radiation Therapy. McDowell LJ; Rock K; Xu W; Chan B; Waldron J; Lu L; Ezzat S; Pothier D; Bernstein LJ; So N; Huang SH; Giuliani M; Hope A; O'Sullivan B; Bratman SV; Cho J; Kim J; Jang R; Bayley A; Ringash J Int J Radiat Oncol Biol Phys; 2018 Oct; 102(2):340-352. PubMed ID: 30191868 [TBL] [Abstract][Full Text] [Related]
4. Effect of Radiotherapy Alone vs Radiotherapy With Concurrent Chemoradiotherapy on Survival Without Disease Relapse in Patients With Low-risk Nasopharyngeal Carcinoma: A Randomized Clinical Trial. Tang LL; Guo R; Zhang N; Deng B; Chen L; Cheng ZB; Huang J; Hu WH; Huang SH; Luo WJ; Liang JH; Zheng YM; Zhang F; Mao YP; Li WF; Zhou GQ; Liu X; Chen YP; Xu C; Lin L; Liu Q; Du XJ; Zhang Y; Sun Y; Ma J JAMA; 2022 Aug; 328(8):728-736. PubMed ID: 35997729 [TBL] [Abstract][Full Text] [Related]
5. Minimally invasive surgery alone compared with intensity-modulated radiotherapy for primary stage I nasopharyngeal carcinoma. Liu YP; Lv X; Zou X; Hua YJ; You R; Yang Q; Xia L; Guo SY; Hu W; Zhang MX; Chen SY; Lin M; Xie YL; Liu LZ; Sun R; Huang PY; Fan W; Guo X; Hong MH; Chen MY Cancer Commun (Lond); 2019 Nov; 39(1):75. PubMed ID: 31730020 [TBL] [Abstract][Full Text] [Related]
6. Quality of life and survival outcome for patients with nasopharyngeal carcinoma treated by volumetric-modulated arc therapy versus intensity-modulated radiotherapy. Huang TL; Tsai MH; Chuang HC; Chien CY; Lin YT; Tsai WL; Fang FM Radiat Oncol; 2020 Apr; 15(1):84. PubMed ID: 32307024 [TBL] [Abstract][Full Text] [Related]
7. Pretreatment quality of life as a predictor of survival for patients with nasopharyngeal carcinoma treated with IMRT. Guo SS; Hu W; Chen QY; Li JM; Zhu SH; He Y; Li JW; Xia L; Ji L; Lin CY; Liu LT; Tang LQ; Guo L; Mo HY; Zhao C; Guo X; Cao KJ; Qian CN; Zeng MS; Hong MH; Shao JY; Sun Y; Ma J; Fan YY; Mai HQ BMC Cancer; 2018 Jan; 18(1):114. PubMed ID: 29386004 [TBL] [Abstract][Full Text] [Related]
8. Risk Assessment of Secondary Primary Malignancies in Nasopharyngeal Carcinoma: A Big-Data Intelligence Platform-Based Analysis of 6,377 Long-term Survivors from an Endemic Area Treated with Intensity-Modulated Radiation Therapy during 2003-2013. Zhang LL; Li GH; Li YY; Qi ZY; Lin AH; Sun Y Cancer Res Treat; 2019 Jul; 51(3):982-991. PubMed ID: 30309219 [TBL] [Abstract][Full Text] [Related]
9. Intensity-modulated radiotherapy provides better quality of life than two-dimensional conventional radiotherapy for patients with stage II nasopharyngeal carcinoma. Pan XB; Huang ST; Chen KH; Jiang YM; Ma JL; Qu S; Li L; Chen L; Zhu XD Oncotarget; 2017 Jul; 8(28):46211-46218. PubMed ID: 28515352 [TBL] [Abstract][Full Text] [Related]
10. Intensity-modulated or conformal radiotherapy improves the quality of life of patients with nasopharyngeal carcinoma: comparisons of four radiotherapy techniques. Fang FM; Tsai WL; Chen HC; Hsu HC; Hsiung CY; Chien CY; Ko SF Cancer; 2007 Jan; 109(2):313-21. PubMed ID: 17154159 [TBL] [Abstract][Full Text] [Related]
11. The Prevalence and Determinants of Return to Work in Nasopharyngeal Carcinoma Survivors. So N; McDowell LJ; Lu L; Xu W; Rock K; Waldron J; Bernstein LJ; Chan HB; Huang SH; Giuliani M; Hope A; O'Sullivan B; Bratman SV; Cho J; Kim J; Jang R; Bayley A; Ringash J Int J Radiat Oncol Biol Phys; 2020 Jan; 106(1):134-145. PubMed ID: 31568813 [TBL] [Abstract][Full Text] [Related]
12. Impact of changes in psychological resilience during treatment with intensity-modulated radiotherapy on nasopharyngeal carcinoma patients: a prospective study. Lu N; Qin T; Hu W Ann Palliat Med; 2022 Jan; 11(1):123-134. PubMed ID: 35144404 [TBL] [Abstract][Full Text] [Related]
13. Early recurrence as a pivotal event in nasopharyngeal carcinoma: identifying predictors and key molecular signals for survivors. Li Y; Huang Z; Zeng X; Pan Y; Wu L; Wang J; Chen R; Xie Y; Lai J; Lin D; Qiu S Head Face Med; 2024 Sep; 20(1):55. PubMed ID: 39342276 [TBL] [Abstract][Full Text] [Related]
14. Replanning during intensity modulated radiation therapy improved quality of life in patients with nasopharyngeal carcinoma. Yang H; Hu W; Wang W; Chen P; Ding W; Luo W Int J Radiat Oncol Biol Phys; 2013 Jan; 85(1):e47-54. PubMed ID: 23122981 [TBL] [Abstract][Full Text] [Related]
15. Clinical features and survival outcomes between ascending and descending types of nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: A big-data intelligence platform-based analysis. Yao JJ; Qi ZY; Liu ZG; Jiang GM; Xu XW; Chen SY; Zhu FT; Zhang WJ; Lawrence WR; Ma J; Zhou GQ; Sun Y Radiother Oncol; 2019 Aug; 137():137-144. PubMed ID: 31102988 [TBL] [Abstract][Full Text] [Related]
16. A cross sectional study in cognitive and neurobehavioral impairment in long-term nasopharyngeal cancer survivors treated with intensity-modulated radiotherapy. McDowell LJ; Ringash J; Xu W; Chan B; Lu L; Waldron J; Rock K; So N; Huang SH; Giuliani M; Hope A; O'Sullivan B; Bratman SV; Cho J; Kim J; Jang R; Bayley A; Bernstein LJ Radiother Oncol; 2019 Feb; 131():179-185. PubMed ID: 30279047 [TBL] [Abstract][Full Text] [Related]
17. Long-term outcomes of replanning during intensity-modulated radiation therapy in patients with nasopharyngeal carcinoma: An updated and expanded retrospective analysis. Zhou X; Wang W; Zhou C; Zhu J; Ding W; Chen M; Chen K; Shi Y; Chen X; Kong FM; Yang H Radiother Oncol; 2022 May; 170():136-142. PubMed ID: 35288229 [TBL] [Abstract][Full Text] [Related]
18. Changes in plasma EBV-DNA and immune status in patients with nasopharyngeal carcinoma after treatment with intensity-modulated radiotherapy. Chen Q; Hu W; Xiong H; Ying S; Ruan Y; Wu B; Lu H Diagn Pathol; 2019 Mar; 14(1):23. PubMed ID: 30871579 [TBL] [Abstract][Full Text] [Related]
19. Outcomes of xerostomia-related quality of life for nasopharyngeal carcinoma treated by IMRT: based on the EORTC QLQ-C30 and H&N35 questionnaires. Bian X; Song T; Wu S Expert Rev Anticancer Ther; 2015 Jan; 15(1):109-19. PubMed ID: 25231774 [TBL] [Abstract][Full Text] [Related]
20. Prognostication of serial post-intensity-modulated radiation therapy undetectable plasma EBV DNA for nasopharyngeal carcinoma. Lee VH; Kwong DL; Leung TW; Choi CW; Lai V; Ng L; Lam KO; Ng SC; Sze CK; Tong CC; Ho PP; Chan WL; Wong LS; Leung DK; Chan SY; Khong PL Oncotarget; 2017 Jan; 8(3):5292-5308. PubMed ID: 28029657 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]